180 related articles for article (PubMed ID: 24387049)
21. Efficacy and safety of oral treprostinil monotherapy for the treatment of pulmonary arterial hypertension: a randomized, controlled trial.
Jing ZC; Parikh K; Pulido T; Jerjes-Sanchez C; White RJ; Allen R; Torbicki A; Xu KF; Yehle D; Laliberte K; Arneson C; Rubin LJ
Circulation; 2013 Feb; 127(5):624-33. PubMed ID: 23307827
[TBL] [Abstract][Full Text] [Related]
22. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension.
Montani D; Chaumais MC; Savale L; Natali D; Price LC; Jaïs X; Humbert M; Simonneau G; Sitbon O
Adv Ther; 2009 Sep; 26(9):813-25. PubMed ID: 19768639
[TBL] [Abstract][Full Text] [Related]
23. Bosentan in systemic sclerosis.
Heresi GA; Minai OA
Drugs Today (Barc); 2008 Jun; 44(6):415-28. PubMed ID: 18596996
[TBL] [Abstract][Full Text] [Related]
24. Cost effectiveness of prostacyclins in pulmonary arterial hypertension.
Roman A; Barberà JA; Escribano P; Sala ML; Febrer L; Oyagüez I; Sabater E; Casado MA
Appl Health Econ Health Policy; 2012 May; 10(3):175-88. PubMed ID: 22452448
[TBL] [Abstract][Full Text] [Related]
25. Early intervention in pulmonary arterial hypertension associated with systemic sclerosis: an essential component of disease management.
Hachulla E; Denton CP
Eur Respir Rev; 2010 Dec; 19(118):314-20. PubMed ID: 21119190
[TBL] [Abstract][Full Text] [Related]
26. Therapeutic challenges for systemic sclerosis: facts and future targets.
Cerinic Matucci M; Del Rosso A; Federico P; Livi R; Fiori G; Bartoli F; Blagojevic J; Tempestini A; Pignone A
Ann N Y Acad Sci; 2007 Sep; 1110():448-54. PubMed ID: 17911460
[TBL] [Abstract][Full Text] [Related]
27. Evidence-based pharmacologic management of pulmonary arterial hypertension.
Benedict N; Seybert A; Mathier MA
Clin Ther; 2007 Oct; 29(10):2134-53. PubMed ID: 18042471
[TBL] [Abstract][Full Text] [Related]
28. Bosentan in pulmonary arterial hypertension secondary to scleroderma.
Joglekar A; Tsai FS; McCloskey DA; Wilson JE; Seibold JR; Riley DJ
J Rheumatol; 2006 Jan; 33(1):61-8. PubMed ID: 16395751
[TBL] [Abstract][Full Text] [Related]
29. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension.
McLaughlin VV; Oudiz RJ; Frost A; Tapson VF; Murali S; Channick RN; Badesch DB; Barst RJ; Hsu HH; Rubin LJ
Am J Respir Crit Care Med; 2006 Dec; 174(11):1257-63. PubMed ID: 16946127
[TBL] [Abstract][Full Text] [Related]
30. Combination therapy in the management of pulmonary arterial hypertension.
Buckley MS; Staib RL; Wicks LM
Int J Clin Pract Suppl; 2013 May; (179):13-23. PubMed ID: 23578069
[TBL] [Abstract][Full Text] [Related]
31. Bosentan therapy of pulmonary arterial hypertension in connective tissue diseases.
Cozzi F; Montisci R; Marotta H; Bobbo F; Durigon N; Ruscazio M; Sfriso P; Iliceto S; Todesco S
Eur J Clin Invest; 2006 Sep; 36 Suppl 3():49-53. PubMed ID: 16919011
[TBL] [Abstract][Full Text] [Related]
32. Survival in systemic sclerosis with pulmonary arterial hypertension has not improved in the modern era.
Rubenfire M; Huffman MD; Krishnan S; Seibold JR; Schiopu E; McLaughlin VV
Chest; 2013 Oct; 144(4):1282-1290. PubMed ID: 23744060
[TBL] [Abstract][Full Text] [Related]
33. Inhaled treprostinil sodium for the treatment of pulmonary arterial hypertension.
Ferrantino M; White RJ
Expert Opin Pharmacother; 2011 Nov; 12(16):2583-93. PubMed ID: 21988216
[TBL] [Abstract][Full Text] [Related]
34. The pulmonary arterial hypertension quality enhancement research initiative: comparison of patients with idiopathic PAH to patients with systemic sclerosis-associated PAH.
Clements PJ; Tan M; McLaughlin VV; Oudiz RJ; Tapson VF; Channick RN; Rubin LJ; Langer A;
Ann Rheum Dis; 2012 Feb; 71(2):249-52. PubMed ID: 21998119
[TBL] [Abstract][Full Text] [Related]
35. Efficacy and safety of novel-targeted drugs in the treatment of pulmonary arterial hypertension: a Bayesian network meta-analysis.
Fu W; He W; Li Y; Chen Y; Liang J; Lei H; Fu L; Chen Y; Ren N; Jiang Q; Shen Y; Ma R; Wang T; Wang X; Zhang N; Xiao D; Liu C
Drug Deliv; 2021 Dec; 28(1):1007-1019. PubMed ID: 34060401
[No Abstract] [Full Text] [Related]
36. Longterm survival among patients with scleroderma-associated pulmonary arterial hypertension treated with intravenous epoprostenol.
Badesch DB; McGoon MD; Barst RJ; Tapson VF; Rubin LJ; Wigley FM; Kral KM; Raphiou IH; Crater GD
J Rheumatol; 2009 Oct; 36(10):2244-9. PubMed ID: 19723905
[TBL] [Abstract][Full Text] [Related]
37. Bosentan improves skin perfusion of hands in patients with systemic sclerosis with pulmonary arterial hypertension.
Rosato E; Molinaro I; Borghese F; Rossi C; Pisarri S; Salsano F
J Rheumatol; 2010 Dec; 37(12):2531-9. PubMed ID: 20810512
[TBL] [Abstract][Full Text] [Related]
38. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
[TBL] [Abstract][Full Text] [Related]
39. Successful treatment with bosentan for pulmonary hypertension and reduced peripheral circulation in juvenile systemic sclerosis.
Shimizu M; Hashida Y; Ueno K; Yokoyama T; Nakayama Y; Saito T; Ohta K; Takehara K; Yachie A
Pediatr Cardiol; 2011 Oct; 32(7):1040-2. PubMed ID: 21789477
[TBL] [Abstract][Full Text] [Related]
40. Long-term effects of inhaled treprostinil in patients with pulmonary arterial hypertension: the Treprostinil Sodium Inhalation Used in the Management of Pulmonary Arterial Hypertension (TRIUMPH) study open-label extension.
Benza RL; Seeger W; McLaughlin VV; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubin LJ
J Heart Lung Transplant; 2011 Dec; 30(12):1327-33. PubMed ID: 22055098
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
